{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:17Z","timestamp":1788866297570,"version":"build-2803163510"},"reference-count":32,"publisher":"Informa UK Limited","issue":"22","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"m Gilead Sciences, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,9,30]]},"DOI":"10.2217\/fon-2017-0528","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T12:14:48Z","timestamp":1521807288000},"page":"2265-2277","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Pathological Assessment of Gastrointestinal Biopsies from Patients with Idelalisib-Associated Diarrhea and Colitis"],"prefix":"10.1080","volume":"14","author":[{"given":"Cecilia CS","family":"Yeung","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA980403, USA"},{"name":"Department of Pathology, University of Washington, Seattle, WA943055, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Hockenbery","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA980403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Westerhoff","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle, WA943055, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Coutre","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA94305-58215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth H","family":"Sedlak","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington, Seattle, WA94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L","family":"Dubowy","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerendra","family":"Munugalavadla","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Taylor","sequence":"additional","affiliation":[{"name":"Icon Cancer Care, South Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"ZYDELIG \u00ae (idelalisib) tablets: for oral use initial U.S. approval: 2014. www.zydelig.com\/include\/media\/pdf\/full-prescribing-information.pdf."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000525"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2016.0022"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000522"},{"key":"e_1_3_5_15_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.tps8618","article-title":"A Phase III, randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)","volume":"31","author":"De Vos S","year":"2013","unstructured":"De Vos S , SehnL, MulliganS, DreylingM, RummelM, ZinzaniP. A Phase III, randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). J. Clin. Oncol.31(Suppl.), Abstract TPS8618 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"e_1_3_5_16_1","article-title":"A Phase 3: randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL)","volume":"32","author":"Eradat HA","year":"2014","unstructured":"Eradat HA , RobakT, DelgadoJ, SchuhA, PristupaAS, Omyla-StaszewskaJ. A Phase 3: randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). J. Clin. Oncol.32(Suppl. 20), Abstract TPS7127 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_5_17_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8500","article-title":"A Phase III, randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)","volume":"31","author":"Leonard J","year":"2013","unstructured":"Leonard J , ZinzaniP, JurczakW, RummelM, SallesG, KimbyE. A Phase III, randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). J. Clin. Oncol.31(Suppl.), Abstract TPS8617 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"e_1_3_5_18_1","article-title":"A Phase 3: randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia","volume":"32","author":"Salles G","year":"2014","unstructured":"Salles G , LamannaN, AminB, BocciaR, GabrailN, ZaydanM. A Phase 3: randomized: double-blind: placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia. J. Clin. Oncol.32(Suppl. 5), Abstract TPS7123 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.404"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000317"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.217240"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.09.004"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409449102"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.008"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.6598"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(03)00139-X"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2707"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.07.002"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707133"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-216343"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01670-2015"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.08.044"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770"},{"key":"e_1_3_5_34_1","unstructured":"Department of veterans affairs pharmacy benefits management services (PBM) medical advisory panel (MAP) visn pharmacist executives (VPES) and the center for medical safety (va medsafe) idelalisib (Zydelig \u00ae ) safety. www.pbm.va.gov\/PBM\/vacenterformedicationsafety\/nationalpbmbulletin\/IDELALISIB_SAFETY_NATIONAL_PBM_BULLETIN_032916_FINAL."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:43Z","timestamp":1719125083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":32,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,9,30]]}},"alternative-id":["10.2217\/fon-2017-0528"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0528","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}